Seventy-five percent of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) who were treated with the antibody ...

Preclinical results indicate new approach could be a way to deliver treatment directly to tumors at higher doses, while reducing side effects in healthy tissue.

HER2-low status discordance between primary and recurrent/metastatic breast cancer in a large-scale cohort. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This abstract does not ...

One of the hotter areas of cancer drug research involves using a particular type of bispecific antibody as the backbone for therapeutic combinations intended to bring a multi-pronged attack to tumors.

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from STRIDE-8, a Phase 3 trial evaluating CAPVAXIVE™ (Pneumococcal ...

Invasive pneumococcal disease declined among children and adults after the introduction of the pediatric heptavalent pneumococcal conjugate vaccine (PCV7) in 2000, but its effect on pneumococcal ...